SARI ANNOUNCES CLOSING OF NMS ACQUISITION

Nerviano (Milano - IT), March 28, 2018 – SARI, a Chinese market-leader biotech investment company, is pleased to announce that it has closed the previously announced agreement to acquire the 90% interests in NMS Group S.p.A., effective from today.

SARI is an affiliate of Shanghai Advanced Research Institute, focused on investment in cutting-edge bio-technology and life-science opportunities, especially targeted cancer therapy. The oncology innovation is the mission of NMS Group S.p.A.. Headquartered in Nerviano, near Milano, in Italy it is an organization covering the whole R&D process: from drug discovery, to preclinical research and clinical development up to manufacturing.

“After tremendous efforts from all parties in the last full year, we eventually made a successful closing on the transaction today. Today is the beginning of a new era of innovation and collaboration in pharmaceutical area between Italy and China” – said Mr.Yi Baxian representative of SARI. “We believe that with the integration of Chinese capital and resources, NMS will certainly rejuvenate and generate prosper achievements, which will contribute to the well being of millions of patients.”

The total value of the deal, a mix of equity injection and debt restructuring, is around 300 mln Euro. For this transaction, SARI, as the leading investor, has established a specific fund together with Nanjing Hicin Pharmaceutical Co. Ltd, V-capital Co. Ltd, and Hefei Dongcheng Industry Investment Co. Ltd..

In addition, the Company announces the appointment of the new Board of Directors of NMS Group S.p.A.:
Mr. Andrea Agazzi (Chairman);
Dr. YI Baxian;
Mr. ZHAO Jianghua;
Mr. XU Jun;
Mr. CAO Xichen;
Ms. Cristina Cagnazzi.

“I’m very happy and proud of the path we have done together with Sari until today” - said NMS Group’ Chairman Andrea Agazzi “and I’m very excited about the development projects we are going to start from tomorrow. The deal preserves the Group's business continuity; enhances present resources and the great tradition of excellence that the world has recognized to NMS, even in the most difficult financial times such as it opens the door to new opportunities of growth and industrial and scientific integration within top-class research environment. The trust that investors have placed in NMS people, concretely represented by their great financial effort, must be repaid by excellent results. This is the commitment that the management assumes with today closing.”

For this closing Sari has been assisted by Bank of China International (China) Limited and Shanghai Pudong Science and Technology Investment Co.,LTD (PDSTI) as financial advisors and by Studio Legale Pedersoli as legal advisor. Bank of China Ltd Milan Branch offered help in the transaction. NMS Group has been assisted by Leonardo-Houlihan Lokey as financial advisor and by Avv. Battistella, Partner of CMS as legal advisor.

SARI is an affiliate of Shanghai Advanced Research Institute. SARI focuses on investment in cutting-edge bio-technology and life-science opportunities, especially targeted cancer therapy.
For this transaction, SARI, as the leading investor, has established a specific fund together with Hicin Pharma, V-capital and FeiDong Investment.

NMS Group is the largest company in Italy committed in innovation and research and development in oncology. With more than 420 total employees, NMS Group employs over 200 qualified researchers involved in research and development, to production. The discovery and applied research of Nerviano Medical Sciences define the innovative heart of the Group and make it an important and international reference in the field of personalized therapy. In these recent years the Centre has capitalized its discoveries in international agreements with most representative pharmaceutical and biotech companies worldwide, such as Ignyta for Entrectinib. NMS also provides pre clinical, clinical and production services addressed to local and international markets, through three different companies: Accelera, one of the few companies engaged in preclinical research in Italy; Clioss engaged in clinical development starting from First-Time-In-Man and Nerpharma, dealing with activities from formulation to production of the active principle.

NMS Group – Nerviano Medical Sciences
Chiara Lattuada
+39 333 84.25.690
mail to: chiara.lattuada@nmsgroup.it

This release was published on openPR.